New drug combo aims to stop HER2-Positive breast cancer from coming back
NCT ID NCT04254263
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 35 times
Summary
This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can further reduce the chance of breast cancer returning in women with HER2-positive breast cancer who still have cancer cells after initial chemotherapy and anti-HER2 treatment. About 316 women with early-stage but locally advanced breast cancer will be randomly assigned to receive either trastuzumab alone or trastuzumab plus pyrotinib for one year. The goal is to see if the combination improves how long women stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.